Analyst Price Targets — FENC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 12, 2026 11:57 am | — | Wedbush | $16.00 | $11.88 | TheFly | Fennec price target raised to $16 from $13 at Wedbush |
| May 22, 2026 10:11 am | — | H.C. Wainwright | $16.00 | $9.97 | TheFly | Fennec price target raised to $16 from $13 at H.C. Wainwright |
| January 8, 2026 10:30 pm | — | Piper Sandler | $18.00 | $7.58 | TheFly | Fennec initiated with an Overweight at Piper Sandler |
| August 15, 2025 1:03 pm | Chase Knickerbocker | Craig-Hallum | $14.00 | $8.54 | TheFly | Fennec price target raised to $14 from $13 at Craig-Hallum |
| May 15, 2024 8:57 am | Chase Knickerbocker | Craig-Hallum | $17.00 | $7.34 | TheFly | Fennec price target lowered to $17 from $20 at Craig-Hallum |
| May 15, 2024 7:22 am | Raghuram Selvaraju | H.C. Wainwright | $15.00 | $7.03 | StreetInsider | Fennec Pharmaceuticals Inc. (FENC) PT Lowered to $15 at H.C. Wainwright |
| April 4, 2024 6:11 am | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $10.77 | TheFly | Fennec price target raised to $18 from $17 at H.C. Wainwright |
| March 19, 2024 9:31 am | Chase Knickerbocker | Craig-Hallum | $18.00 | $11.01 | StreetInsider | Fennec Pharmaceuticals Inc. (FENC) PT Raised to $18 at Craig-Hallum |
| November 22, 2022 8:25 am | — | Cantor Fitzgerald | $12.00 | $9.17 | Benzinga | Cantor Fitzgerald Upgrades Fennec Pharmaceuticals to Overweight, Raises Price Target to $12 |
| September 26, 2022 10:01 am | — | Wedbush | $19.00 | $7.11 | Benzinga | Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $19 |
Latest News for FENC
Adherex Technologies (NASDAQ: FENC - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability. Analyst Recommendations This is a summary of recent
~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~
The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FENC.
U.S. House Trading
No House trades found for FENC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.